Literature DB >> 21108515

Simultaneous optical coherence tomography and laser induced fluorescence imaging in rat model of ovarian carcinogenesis.

Lida P Hariri1, Erica R Liebmann, Samuel L Marion, Patricia B Hoyer, John R Davis, Molly A Brewer, Jennifer K Barton.   

Abstract

Determining if an ovarian mass is benign or malignant is an ongoing clinical challenge. The development of reliable animal models provides means to evaluate new diagnostic tools to more accurately determine if an ovary has benign or malignant features. Although sex cord-stromal tumors (SCST) account for 0.1–0.5% of ovarian malignancies, they have similar appearances to more aggressive epithelial cancers and can serve as a prototype for developing better diagnostic methods for ovarian cancer. Optical coherence tomography (OCT) and laser-induced fluorescence (LIF) spectroscopy are non-destructive optical imaging modalities. OCT provides architectural cross-sectional images at near histological resolutions and LIF provides biochemical information. We utilize combined OCT-LIF to image ovaries in post-menopausal ovarian carcinogenesis rat models, evaluating normal cyclic, acyclic and neoplastic ovaries. Eighty-three female Fisher rats were exposed to combinations of control sesame oil, 4-vinyl cyclohexene diepoxide (VCD) to induce ovarian failure,and/or 7,12-dimethylbenz[a]anthracene (DMBA) to induce carcinogenesis. Three or five months post-treatment, 162 ovaries were harvested and imaged with OCT-LIF: 40 cyclic, 105 acyclic and 17 SCST. OCT identified various follicle stages,corpora lutea (CL), CL remnants, epithelial invaginations/inclusions and allowed for characterization of both cystic and solid SCST. Signal attenuation comparisons between CL and solid SCST revealed statistically significant increases in attenuation among CL. LIF characterized spectral differences in cyclic, acyclic and neoplastic ovaries attributed to collagen, NADH/FAD and hemoglobin absorption. We present combined OCT-LIF imaging in a rat ovarian carcinogenesis model, providing preliminary criteria for normal cyclic, acyclic and SCST ovaries which support the potential of OCT-LIF for ovarian imaging.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21108515      PMCID: PMC3040967          DOI: 10.4161/cbt.10.5.12531

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  37 in total

Review 1.  Cellular and functional optical coherence tomography of the human retina: the Cogan lecture.

Authors:  Wolfgang Drexler
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-12       Impact factor: 4.799

2.  High-resolution imaging of gynecologic neoplasms using optical coherence tomography.

Authors:  C Pitris; A Goodman; S A Boppart; J J Libus; J G Fujimoto; M E Brezinski
Journal:  Obstet Gynecol       Date:  1999-01       Impact factor: 7.661

3.  Dual modality imaging of a novel rat model of ovarian carcinogenesis.

Authors:  Elizabeth M Kanter; Ross M Walker; Samuel L Marion; Molly Brewer; Patricia B Hoyer; Jennifer K Barton
Journal:  J Biomed Opt       Date:  2006 Jul-Aug       Impact factor: 3.170

4.  Endoscopic optical coherence tomography and laser-induced fluorescence spectroscopy in a murine colon cancer model.

Authors:  Lida P Hariri; Alexandre R Tumlinson; David G Besselsen; Urs Utzinger; Eugene W Gerner; Jennifer K Barton
Journal:  Lasers Surg Med       Date:  2006-04       Impact factor: 4.025

5.  Characterization of rat ovarian adenocarcinomas developed in response to direct instillation of 7,12-dimethylbenz[a]anthracene (DMBA) coated suture.

Authors:  Keith A Crist; Zhongqiu Zhang; Ming You; William T Gunning; Phillip B Conran; Vernon E Steele; Ronald A Lubet
Journal:  Carcinogenesis       Date:  2005-02-03       Impact factor: 4.944

6.  Alterations of the extracellular matrix in ovarian cancer studied by Second Harmonic Generation imaging microscopy.

Authors:  Oleg Nadiarnykh; Ronald B LaComb; Molly A Brewer; Paul J Campagnola
Journal:  BMC Cancer       Date:  2010-03-11       Impact factor: 4.430

7.  Comprehensive microscopy of the esophagus in human patients with optical frequency domain imaging.

Authors:  Melissa J Suter; Benjamin J Vakoc; Patrick S Yachimski; Milen Shishkov; Gregory Y Lauwers; Mari Mino-Kenudson; Brett E Bouma; Norman S Nishioka; Guillermo J Tearney
Journal:  Gastrointest Endosc       Date:  2008-10       Impact factor: 9.427

8.  Lack of modifying effects of an estrogenic compound atrazine on 7,12-dimethylbenz(a)anthracene-induced ovarian carcinogenesis in rats.

Authors:  Takuji Tanaka; Hiroyuki Kohno; Rikako Suzuki; Shigeyuki Sugie
Journal:  Cancer Lett       Date:  2004-07-16       Impact factor: 8.679

Review 9.  Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Int J Gynecol Pathol       Date:  2008-04       Impact factor: 2.762

10.  Activation of mitogen-activated protein kinases and AP-1 transcription factor in ovotoxicity induced by 4-vinylcyclohexene diepoxide in rats.

Authors:  Xiaoming Hu; Jodi A Flaws; I Glenn Sipes; Patricia B Hoyer
Journal:  Biol Reprod       Date:  2002-09       Impact factor: 4.285

View more
  18 in total

1.  Three-dimensional texture analysis of optical coherence tomography images of ovarian tissue.

Authors:  Travis W Sawyer; Swati Chandra; Photini F S Rice; Jennifer W Koevary; Jennifer K Barton
Journal:  Phys Med Biol       Date:  2018-12-04       Impact factor: 3.609

2.  Modeling perimenopause in Sprague-Dawley rats by chemical manipulation of the transition to ovarian failure.

Authors:  Jennifer B Frye; Ashley L Lukefahr; Laura E Wright; Sam L Marion; Patricia B Hoyer; Janet L Funk
Journal:  Comp Med       Date:  2012-06       Impact factor: 0.982

3.  Ultrahigh speed spectral-domain optical coherence microscopy.

Authors:  Hsiang-Chieh Lee; Jonathan J Liu; Yuri Sheikine; Aaron D Aguirre; James L Connolly; James G Fujimoto
Journal:  Biomed Opt Express       Date:  2013-07-01       Impact factor: 3.732

4.  Ultraminiature optical design for multispectral fluorescence imaging endoscopes.

Authors:  Tyler H Tate; Molly Keenan; John Black; Urs Utzinger; Jennifer K Barton
Journal:  J Biomed Opt       Date:  2017-03-01       Impact factor: 3.170

5.  Molecular Imaging in Optical Coherence Tomography.

Authors:  Scott P Mattison; Wihan Kim; Jesung Park; Brian E Applegate
Journal:  Curr Mol Imaging       Date:  2014-07-01

6.  In vivo molecular imaging of colorectal cancer using quantum dots targeted to vascular endothelial growth factor receptor 2 and optical coherence tomography/laser-induced fluorescence dual-modality imaging.

Authors:  Jordan L Carbary-Ganz; Weston A Welge; Jennifer K Barton; Urs Utzinger
Journal:  J Biomed Opt       Date:  2015       Impact factor: 3.170

7.  Simultaneous multiplane imaging of human ovarian cancer by volume holographic imaging.

Authors:  Gabriel V Orsinger; Jennifer M Watson; Michael Gordon; Ariel C Nymeyer; Erich E de Leon; Johnathan W Brownlee; Kenneth D Hatch; Setsuko K Chambers; Jennifer K Barton; Raymond K Kostuk; Marek Romanowski
Journal:  J Biomed Opt       Date:  2014-03       Impact factor: 3.170

8.  Analysis of second-harmonic-generation microscopy in a mouse model of ovarian carcinoma.

Authors:  Jennifer M Watson; Photini F Rice; Samuel L Marion; Molly A Brewer; John R Davis; Jeffrey J Rodriguez; Urs Utzinger; Patricia B Hoyer; Jennifer K Barton
Journal:  J Biomed Opt       Date:  2012-07       Impact factor: 3.170

9.  Diagnostic potential of multimodal imaging of ovarian tissue using optical coherence tomography and second-harmonic generation microscopy.

Authors:  Weston A Welge; Andrew T DeMarco; Jennifer M Watson; Photini S Rice; Jennifer K Barton; Matthew A Kupinski
Journal:  J Med Imaging (Bellingham)       Date:  2014-07-18

10.  Quantum dots targeted to vascular endothelial growth factor receptor 2 as a contrast agent for the detection of colorectal cancer.

Authors:  Jordan L Carbary-Ganz; Jennifer K Barton; Urs Utzinger
Journal:  J Biomed Opt       Date:  2014-08       Impact factor: 3.170

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.